A Multicenter Phase II Study of AMG 337 in Patients with MET-Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other MET-Amplified Solid Tumors
暂无分享,去创建一个
E. Van Cutsem | Yoon-Koo Kang | D. Cunningham | B. Karaszewska | S. Siena | H. Chung | Hui Yang | N. Go | V. Shankaran | M. Schupp
[1] R. Loberg,et al. Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors , 2018, Clinical Cancer Research.
[2] D. Cunningham,et al. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2017, The Lancet. Oncology.
[3] M. Shah,et al. Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial , 2017, JAMA oncology.
[4] A. Bardelli,et al. Integrating liquid biopsies into the management of cancer , 2017, Nature Reviews Clinical Oncology.
[5] Nathan T. Fried,et al. The Role of Adenosine Signaling in Headache: A Review , 2017, Brain sciences.
[6] E. Smyth,et al. Immunotherapy for Gastroesophageal Cancer , 2016, Journal of clinical medicine.
[7] K. Rex,et al. In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models , 2016, Molecular Cancer Therapeutics.
[8] C. Mathers,et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.
[9] R. Donehower,et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. , 2014, The Lancet. Oncology.
[10] R. Loberg,et al. First-in-human study of AMG 337, a highly selective oral inhibitor of MET, in adult patients (pts) with advanced solid tumors. , 2014 .
[11] Jeffrey W. Clark,et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Laura H. Tang,et al. MET Expression and Amplification in Patients with Localized Gastric Cancer , 2011, Cancer Epidemiology, Biomarkers & Prevention.
[13] L. Trusolino,et al. Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition , 2010, Molecular Cancer.
[14] A. Hölscher,et al. The overexpression of c-met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation. , 2008, Oncology reports.
[15] A. Norman,et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. , 2008, The New England journal of medicine.
[16] R. Shapiro. Caffeine and headaches , 2007, Neurological Sciences.
[17] J. Ajani,et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] T. Godfrey,et al. The HGF receptor c-Met is overexpressed in esophageal adenocarcinoma. , 2005, Neoplasia.
[19] T. Hirao,et al. The prognostic significance of amplification and overexpression of c‐met and c‐erb B‐2 in human gastric carcinomas , 1999, Cancer.
[20] Hiroshi Yamamoto,et al. The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c‐met), autocrine motility factor receptor, and urokinase‐type plasminogen activator receptor , 1998, Cancer.
[21] Carmen Birchmeier,et al. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud , 1995, Nature.
[22] Tetsuo Noda,et al. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor , 1995, Nature.
[23] M. Sharpe,et al. Scatter factor/hepatocyte growth factor is essential for liver development , 1995, Nature.
[24] B. Nordlinger,et al. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[25] U. Fischer,et al. Amplification of the met gene in glioma , 1995, Genes, chromosomes & cancer.
[26] H. Ito,et al. Frequent amplification of the c-met gene in scirrhous type stomach cancer. , 1992, Biochemical and biophysical research communications.
[27] L. Orci,et al. Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor , 1991, Cell.
[28] J Vandekerckhove,et al. Scatter factor: molecular characteristics and effect on the invasiveness of epithelial cells , 1990, The Journal of cell biology.
[29] M. Ladanyi,et al. Gene amplification in gastric and esophageal adenocarcinomas. , 1990, Cancer research.
[30] E. S. Pearson,et al. THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL , 1934 .